Diffusion Pharmaceuticals (DFFN) Reports Significant Progress in its Strategic Review Process
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
- Devon Energy to sell Eagle Ford assets to Crescent Energy for $4.2B
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
November 14, 2022 6:30 AM ESTDiffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process
Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital
LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Clients Offer
Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process
Date of Diffusions 2022 Annual Meeting of Stockholders Set for December 30, 2022
CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion... More



